"This partnership is a powerful example o how novel care models can complement traditional care to expand access," said Victor Sadauskas, MD, CEO of Kivo Health. "Together with Priority Health, we're ...

GSK GSK stock has risen 18.6% in the past three months. The price recovery was backed by strong third-quarter results, ...

Non-cystic fibrosis bronchiectasis (NCFB) is a heterogeneous disease characterised by a ‘vicious vortex’ of ...

More than 11.7 million Americans live with chronic obstructive pulmonary disease (COPD), and West Virginia has one of the highest rates in the country, with more than 186,000 adults affected.

ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patientsGlasmacinal, a novel macrolide, was well tolerated ...

In both adults with and without self-reported COPD, a 6- or 12-week course of cytisinicline helped more daily smokers achieve ...

The pulmonary emphysema market is poised for steady growth driven by rising COPD prevalence, an aging global population, and greater diagnostic awareness. Advances in inhaled therapies, targeted ...

This simple diagram shows a healthy lung (left) and one with chronic obstructive pulmonary disease, or COPD. (AdobeStock) Buy Photo The Gazette offers audio versions of articles using Instaread. Some ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized trials ...

Using a care pathway focused on chronic obstructive pulmonary disease (COPD) can lead to shorter hospital stays, increased referrals to pulmonary rehabilitation, and improved standardization of care, ...

Verona Pharma's stock soars into record territory after buyout deal with Merck Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant's portfolio of ...